Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma

NCT01440816 is registered in ClinicalTrials.gov with OncoSec Medical Incorporated as lead sponsor.

NCT NCT01440816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01440816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma
Lead sponsor
OncoSec Medical Incorporated
Phase
Phase 2
Overall status
Completed
Start date
January 3, 2012
Completion date
April 10, 2015
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma